Activate is planting its roots in Houston with a plan to have its first set of fellows next year. Photo via Getty Images

An organization that directs support to scientists developing impactful technology has decided on Houston for its fifth program.

Activate was founded in Berkeley, California, in 2015 to bridge the gap between the federal and public sectors to deploy capital and resources into the innovators creating transformative products. The nonprofit expanded its programs to Boston and New York before launching a virtual fellowship program — Activate Anywhere, which is for scientists 50 or more miles outside one of the three hubs.

"Our mission is to empower scientists to reinvent the world by bringing their research to market," Aimee Rose, executive managing director of Activate, tells InnovationMap. "There's so much technical talent that we educate in this country every year and so many amazing inventions that happen, that combining the two, which is the sort of inventor/entrepreneur, and giving them the support mechanisms they need to get on their feet and be successful, has the potential to unlock an incredible amount of value for the country, for the environment, and to address other social problems."

This year, Activate is planting seeds in Houston to grow a presence locally and have its first set of fellows in 2024. While Activate is industry agnostic, Rose says a big draw from Houston is the ability to impact the future of energy.

"We're super excited about Houston as an emerging ecosystem for the clean energy transition as being the energy capital of the world, as well as all the other emerging players there are across the landscape in Houston," Rose says. "I think we can move the needle in Houston because of our national footprint."

The first order of business, Rose says, is hiring a managing director for Activate Houston. The job, which is posted online, is suited for an individual who has already developed a hardtech business and has experience and connections within Houston's innovation ecosystem.

"We want to customize the program so that it makes the most sense for the community," Rose says about the position. "So, somebody that has the relationships and the knowledge of the ecosystem to be able to do that and somebody that's kind of a mentor at heart."

The program is for early-stage founders — who have raised less than $2 million in funding — working on high-impact technology. Rose explains that Activate has seen a number of microelectronics and new materials companies go through the program, and, while medical innovation is impactful, Activate doesn't focus on pharmaceutical or therapeutic industries since there are existing pathways for those products.

Ultimately, Activate is seeking innovators whose technologies fall through the cracks of existing innovation infrastructure.

"Not every business fits into the venture capital model in terms of what investors would expect to be eventual outcomes, but these these types of businesses can still have significant impact and make the world a better place," Rose says, explaining how Activate is different from an incubator or accelerator. "As opposed as compared to a traditional incubator, this is a very high touch program. You get a living stipend so you can take a big business technical risk without a personal risk. We give you a lot of hands on support and mentoring."

Each of the programs selects 10 fellows that join the program for two years. The fellows receive a living stipend, connections from Activate's robust network of mentors, and access to a curriculum specific to the program.

Since its inception, Activate has supported 104 companies and around 146 entrepreneurs associated with those companies. With the addition of Houston, Activate will be able to back 50 individuals a year.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

MD Anderson launches $10M joint venture to advance personalized cancer treatment tech

fighting cancer

The University of Texas MD Anderson Cancer Center and Japan’s TOPPAN Holdings Inc. have formed a joint venture to co-develop TOPPAN Holdings’ 3D cell culture, or organoid, technology known as invivoid.

The technology will be used as a tool for personalized cancer treatments and drug screening efforts, according to a release from MD Anderson. TOPPAN has committed $10 million over five years to advance the joint research activities.

“The strategic alliance with MD Anderson paves a promising path toward personalized cancer medicine," Hiroshi Asada, head of the Business Innovation Center at TOPPAN Holdings, said in a news release.

Invivoid is capable of establishing organoid models directly from patient biopsies or other tissues in a way that is faster and more efficient. Researchers may be able to test a variety of potential treatments in the laboratory to understand which approach may work best for the patient, if validated clinically.

“Organoids allow us to model the three-dimensional complexity of human cancers in the lab, thus allowing us to engineer a powerful translational engine—one that could not only predict how patients will respond to therapy before treatment begins but also could help to reimagine how we discover and validate next-generation therapies," Dr. Donna Hansel, division head of pathology and laboratory medicine at MD Anderson, added in the news release. “Through this collaboration, we hope to make meaningful progress in modeling cancer biology for therapeutic innovation.”

The joint venture will build upon preclinical research previously conducted by MD Anderson and TOPPAN. The organizations will work collaboratively to obtain College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) certifications for the technology, which demonstrate a commitment to high-quality patient care. Once the certifications are obtained, they plan to conduct observational clinical studies and then prospective clinical studies.

“We believe our proprietary invivoid 3D cell culture technology, by enabling the rapid establishment of organoid models directly from patient biopsies, has strong potential to help identify more effective treatment options and reduce the likelihood of unnecessary therapies,” Asada added in the release. “Through collaboration on CAP/CLIA certification and clinical validation, we aim to bring this innovation closer to real-world patient care and contribute meaningfully to the advancement of cancer medicine."

NASA taps Houston-area company to explore low-cost spacecraft delivery

Webster-based Arrow Science and Technology is one of six companies picked by NASA to study low-cost ways to launch and deliver spacecraft for difficult-to-reach orbits.

In all, nine studies will be performed under a roughly $1.4 million award from NASA. Another Texas company, Cedar Park-based Firefly Aerospace, is also among the six companies working on the studies.

“With the increasing maturity of commercial space delivery capabilities, we’re asking companies to demonstrate how they can meet NASA’s need for multispacecraft and multiorbit delivery to difficult-to-reach orbits beyond current launch service offerings,” Joe Dant, a leader of the Launch Services Program at NASA’s Kennedy Space Center in Florida, said in a news release. “This will increase unique science capability and lower the agency’s overall mission costs.”

Arrow is teaming up with Rockville, Maryland-based Quantum Space for its study. Quantum’s Ranger orbital transfer vehicle provides payload delivery services for spacecraft heading to low-Earth and lunar orbits.

Arrow, a Native American-owned small business, offers technical support and hardware manufacturing services for the space and defense industries.

James Baker, founder and president of Arrow, said in a news release that the combination of his company’s deployment systems with Quantum’s Ranger vehicle “allows our customers the ability to focus on the development of their payload[s] while we take care of getting them where they need to be.”

“This is an exciting opportunity to demonstrate the unique capabilities of our highly maneuverable Ranger spacecraft, which will expand NASA’s options for reaching dynamic and challenging … orbits,” Kerry Wisnosky, CEO of Quantum Space, added in the release.

The nine studies are scheduled to be completed by mid-September.

NASA said it will use the studies’ findings “to inform mission design, planning, and commercial launch acquisition strategies for risk-tolerant payloads, with a possibility of expanding delivery services to larger-sized payloads and to less risk-tolerant missions in the future.”

ExxonMobil may pause plans for $7 billion Baytown hydrogen plant

Change of Plans

Spring-based ExxonMobil, the country’s largest oil and gas company, might delay or cancel what would be the world’s largest low-carbon hydrogen plant due to a significant change in federal law. The project carries a $7 billion price tag.

The Biden-era Inflation Reduction Act created a new 10-year incentive, the 45V tax credit, for production of clean hydrogen. But under President Trump’s "One Big Beautiful Bill Act," the window for starting construction of low-carbon hydrogen projects that qualify for the tax credit has narrowed. The Inflation Reduction Act mandated that construction start by 2033. But the Big Beautiful Bill switched the construction start time to early 2028.

“While our project can meet this timeline, we’re concerned about the development of a broader market, which is critical to transition from government incentives,” ExxonMobil Chairman and CEO Darren Woods said during the company’s recent second-quarter earnings call.

Woods said ExxonMobil is working to determine whether a combination of the 45Q tax credit for carbon capture projects and the revised 45V tax credit will help pave the way for a “broader” low-carbon hydrogen market.

“If we can’t see an eventual path to a market-driven business, we won’t move forward with the [Baytown] project,” Woods said.

“We knew that helping to establish a brand-new product and a brand-new market initially driven by government policy would not be easy or advance in a straight line,” he added.

Woods said ExxonMobil is trying to nail down sales contracts connected to the project, including exports of ammonia to Asia and Europe and sales of hydrogen in the U.S.

ExxonMobil announced in 2022 that it would build the low-carbon hydrogen plant at its refining and petrochemical complex in Baytown. The company has said the plant is slated to go online in 2027 and 2028.

As it stands now, ExxonMobil wants the Baytown plant to produce up to 1 billion cubic feet of hydrogen per day made from natural gas, and capture and store more than 98 percent of the associated carbon dioxide. The company has said the project could store as much as 10 million metric tons of CO2 per year.

---

This article originally appeared on EnergyCapitalHTX.com.